Invest in the #FutureofMedicine with CEO, Troy Grogan
Olivia: Troy, thanks for being with us. I'm excited to be talking about the digital healthcare space today. There are so many headlines about the industry's boom. I wanted to get your take on things. Can you share your perspective on the current market?
Troy: I always encourage people interested in this space to dive deeper than just the surface level of the industry as a whole. While the whole industry is booming, other segments of this market outpace the industry as a whole - like the rollout of remote healthcare services like telemedicine and remote patient monitoring. As a result, we see this space positioned to triple in size over the next five years to more than $150 billion.
Olivia: Do you think COVID-19 is playing a role in speeding up this market growth?
Troy: The healthcare industry has always pioneered innovation and adaptability, flourishing because of leaders who provide solutions that work towards a shared goal, better health for all. Most people agree that medical technology is a field that will remain steady through the market and global fluctuations and is an expressed area of interest for investors. With the novel COVID-19 pandemic sweeping the globe and continuing to make headlines daily, the industry remains nimble, and the focus is quickly becoming remote, physician-directed patient monitoring.
Olivia: Can you give us a comparison to another company in the space that has seen success?
Troy: The idea of remote patient monitoring isn't new. In the 1940s, a company named Holter developed a battery-powered heart monitor. Five decades later, healthcare startup leader Jim Sweeny, Founder of CardioNet, launched a product in 1999 to manage cardiac patients around the clock, noticed and adopted by industry giants like Medicare. Sweeny found himself a $2.5 billion niche opportunity, merged with BioTel, BioTelemetry, Inc. was founded and went public. The company's value has more than quadrupled. USAQ and BioTelemetry are both rooted in the shared goal of providing better outcomes for their patients and adapting to digital health solutions' demands. For too long, conventional medicine has focused on treatment rather than prevention. Both USAQ and BioTelemetry are focused on lowering the risk of disease or health incidents before they occur. However, USAQ's product line is much more robust and will address cardiovascular disease, diabetes, metabolic syndrome, obesity, asthma, and allergies through their cloud-based platform. Our primary care physician clients have patients that suffer from allergies and obesity, thought to be signs or markers of things going wrong with a patient's immune system. Allergies and obesity can lead to subsequent complications, such as cardiovascular disease, diabetes, metabolic syndrome, chronic obstructive pulmonary disease (COPD), and high blood pressure. Pharmacological treatment, or the obligatory lecture, has not worked with many of these patients. By implementing USAQ's innovative preventive health platform, patients can be more effectively managed to a healthier status by their primary care provider.
Olivia: Why is this the time to invest in a company like USAQ?
Troy: We're in the pre-revenue phase as a publicly-traded company. Making an early investment into USAQ offers you the unique (albeit time-sensitive!) opportunity not only to be a part but owning a part of the digital healthcare revolution.
As a pre-revenue public company, our stock trades much lower than our counterparts with products already in the market. It's essential to look at those same companies' trajectory for insight into an early investor's financial possibilities, like BioTelemetry. The pre-revenue phase is a unique opportunity for investors. Most investors don't have access to opportunities like this like venture capitalists do, and that's after they've made 5-7x the upside on their investment. It's the time, and the market continues to reinforce that.
Olivia: If someone is interested in investing, what are the next steps?
Troy: Visit our website, usaqcorp.com, find us through your brokerage (we're stock symbol USAQ), or reach out to our client relations team to schedule a consultation. Whether you're a physician, someone interested in investing, or a member of the wellness-aware community, we are looking forward to talking with you soon.
OUR STOCK SYMBOL: USAQ
Investor & Media Contact:
Olivia Giamanco
USA Equities Corp
(929) 379-6503
IR@USAQCORP.COM